S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
NYSEAMERICAN:PTN

Palatin Technologies - PTN Stock Forecast, Price & News

$3.01
-0.09 (-2.90%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.84
$3.04
50-Day Range
N/A
52-Week Range
$2.14
$13.00
Volume
36,202 shs
Average Volume
89,095 shs
Market Capitalization
$28.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Palatin Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,893.4% Upside
$60.00 Price Target
Short Interest
Healthy
3.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.62) to ($3.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars


PTN stock logo

About Palatin Technologies (NYSEAMERICAN:PTN) Stock

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

PTN Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Earnings Outlook For Palatin Technologies
Palatin Receives $4.7 Million of Non-Dilutive Funding
Palatin Announces $10 Million Registered Direct Offering
See More Headlines
Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

PTN Company Calendar

Last Earnings
11/15/2021
Today
3/25/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PTN
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$60.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+1,561.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,200,000.00
Net Margins
-1,713.72%
Pretax Margin
-1,713.63%

Debt

Sales & Book Value

Annual Sales
$1.47 million
Book Value
$1.76 per share

Miscellaneous

Free Float
8,410,000
Market Cap
$28.08 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Carl Spana
    President, Chief Executive Officer & Director
  • Stephen T. Wills
    COO, CFO, Secretary, Treasurer & Executive VP
  • Michael B. Raizman
    Chief Medical Officer
  • John Dodd
    Senior Vice President-Preclinical Development
  • James E. Hattersley
    Senior Vice President-Business Development













PTN Stock - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings
or view top-rated stocks.

What is Palatin Technologies' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year target prices for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,893.4% from the stock's current price.
View analysts price targets for PTN
or view top-rated stocks among Wall Street analysts.

How have PTN shares performed in 2023?

Palatin Technologies' stock was trading at $3.87 at the beginning of 2023. Since then, PTN shares have decreased by 22.2% and is now trading at $3.01.
View the best growth stocks for 2023 here
.

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our PTN earnings forecast
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The biopharmaceutical company had revenue of $0.16 million for the quarter. Palatin Technologies had a negative trailing twelve-month return on equity of 169.74% and a negative net margin of 1,713.72%. During the same period in the prior year, the business earned ($0.50) earnings per share.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.07%), Geode Capital Management LLC (0.71%), Millennium Management LLC (0.49%), Dimensional Fund Advisors LP (0.19%), Morgan Stanley (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr.
View institutional ownership trends
.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $3.01.

How much money does Palatin Technologies make?

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $28.08 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($3.95) on an earnings per share basis.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202.

This page (NYSEAMERICAN:PTN) was last updated on 3/26/2023 by MarketBeat.com Staff